Why the study?
Multiple studies and clinical trials, including data from DOAC trials, changed the treatment and prophylaxis landscape of VTE in cancer patients, requiring an update to the 2014 SEOM guideline.
This 2019 update of the SEOM clinical guideline incorporates new evidence, including DOACs, for the treatment and prophylaxis of VTE in cancer patients.
Supports prioritizing DOACs for cancer-associated VTE; extends prior guidelines with recent RCT data.
In 2011, the Spanish Society of Medical Oncology (SEOM) first published a clinical guideline of venous thromboembolism (VTE) and cancer. This guideline was updated in 2014, and since then, multiple studies and clinical trials have changed the landscape of the treatment and prophylaxis of VTE in cancer patients. To incorporate the most recent evidence, including data from direct oral anticoagulants (DOACs) randomized clinical trials, SEOM presents a new update of the guideline.
No takes yet. Share an insight, caveat, or question.
Martín et al. (2020) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: